John Kane, MD, shared new positive phase 2 data on N-methyl amisulpride (LB-102) for the treatment of patients with acutely exacerbated schizophrenia at the 2025 Annual Congress of the Schizophrenia International Research Society.

Dr Carsten Rudolph, Cofounder and Chief Executive Officer at Ethris, said that from a partnering perspective, he observed some shifts in trends.

Many drug manufacturers, healthcare providers, and patients see the potential benefits of producing autologous therapies at the point of care (POC). However, even among its proponents, there is less agreement on the best path forward, says AltruBio CEO Judy Chou, Ph.D.

Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rectify’s groundbreaking approach to drugging membrane proteins, and how his team is tackling rare hepatobiliary diseases with small-molecule therapies.

Oncolytics Biotech has a treatment in development for breast, pancreatic, and anal cancer. Pharmaceutical Executive spoke with chief medical officer Thomas C. Heineman, MD, PhD, and vice president of business development Christophe Degois about the company’s pipeline and financial status.

Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today’s guest, who has TD1, explains how he turned his passion for helping others into innovative treatments for diabetes and other chronic diseases.

This time around, we note that Sernova Biotherapeutics hired Pericles Calias as chief development officer and head of R&D. Previously, he served as interim chief development officer at Vibe Bio, in addition to doing consulting and board work.

Life Biosciences, the company co-founded by the Harvard study’s lead author Dr David Sinclair, is gearing up to launch the first ever partial epigenetic reprogramming candidate into the clinic this year.